Posters and Presentations
04/14/2024
Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features
04/16/2024
Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults
04/16/2024
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
04/17/2024
Characterization of BHV-7000: A Novel Kv7/2/7.3 Activator for the Treatment of Seizures
04/17/2024
Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review
12/01/2023
Determinants of Health-Related Quality of Life of Patients With Focal Epilepsy: A Systematic Literature Review
12/01/2023
Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures
12/01/2023
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
12/01/2023
Functional Impairments in Patients With KCNQ2-DEE: Associations Among Key Clinical Features
12/01/2023
A First in Human Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults
09/02/2023
Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy
03/13/2023
Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy
12/03/2022
Effects of retigabine and the novel M-current activator BHV-7000 on epilepsy-associated KCNQ2 variants
04/14/2024
Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole
04/14/2024
Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects
04/15/2024
Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders
04/15/2024
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects
04/15/2024
No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole
04/16/2024
Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia
04/16/2024
Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxias
04/16/2024
Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia
04/17/2024
Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia
3/3/2024
Content Validity of the Friedreich’s Ataxia Rating Scale – Activities of Daily Living (FARS-ADL) for Use in Patients With Spinocerebellar Ataxia (SCA)
3/3/2024
Measurement Properties of the Friedreich’s Ataxia Rating Scale–Activities of Daily Living in Patients With Spinocerebellar Ataxia
3/3/2024
Automated Video-Based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects With Spinocerebellar Ataxia
3/4/2024
Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6 through the Eyes of Patients: Burden of Illness and Quality of Life
5/25/2023
Understanding the Spectrum of SCA1, SCA2, SCA3, and SCA6 Through the Eyes of Patients: Burden of Illness Perspectives.
6/1/2023
Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder
11/17/2022
Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder
06/20/2023
Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy
03/20/2023
Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy
12/09/2023
Expansion, Persistence, and Characteristics of Autologous, BHV-1100 ARMored Memory-Like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+, Multiple Myeloma Patients
09/27/2023
Expansion, Persistence, and Characteristics of Autologous, BHV-1100 ARMored Memory-Like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+, Newly Diagnosed Multiple Myeloma Patients
04/14/2024
Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson's Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases
04/14/2024
Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson's Disease Progression in Untreated Patients Using Parkinson's Progression Markers Initiative Data
04/17/2024
Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson's Disease Progression Using Parkinson's Progression Markers Initiative Natural History Data
3/8/2024
Association of Anti-Inflammatory Therapy Use With the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients With Autoimmune Diseases
3/8/2024
Weighting MDS-UPDRS motor items for optimal sensitivity to Parkinson’s Disease progression in untreated patients using Parkinson’s Progression Markers Initiative data
3/8/2024
Weighting MDS-UPDRS Part II items for optimal sensitivity to Parkinson’s disease progression using Parkinson’s Progression Markers Initiative natural history data